Gene therapy of inherited and acquired hearing loss

Project Information

iHEAR

Grant agreement ID: 819531

DOI

10.3030/819531

Project closed

EC signature date 12 February 2019

Start date 1 May 2019

End date 31 October 2024

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 1 999 500,00

EU contribution

€ 1 999 500,00

Coordinated by

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (12)

Protection from cisplatin-induced hearing loss with lentiviral vector-mediated ectopic expression of the anti-apoptotic protein BCL-XL

Author(s): Larissa Nassauer, Hinrich Staecker, Peixin Huang, Bryan Renslo, Madeleine Goblet, Jennifer Harre, Athanasia Warnecke, Juliane W. Schott, Michael Morgan, Melanie Galla, Axel Schambach
Published in: Molecular Therapy - Nucleic Acids, Issue 35, 2024, Page(s) 102157, ISSN 2162-2531
Publisher: Nature Publishing Group
DOI: 10.1016/j.omtn.2024.102157

The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells

Author(s): Larissa Nassauer, Juliane W. Schott, Jennifer Harre, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach
Published in: Journal of Molecular Medicine, Issue 102, 2024, Page(s) 1163-1174, ISSN 0946-2716
Publisher: Springer Verlag
DOI: 10.1007/s00109-024-02472-2

Gene therapy as a possible option to treat hereditary hearing loss

Author(s): Michael Morgan, Juliane W. Schott, Axel Rossi, Christian Landgraf, Athanasia Warnecke, Hinrich Staecker, Anke Lesinski-Schiedat, Brigitte Schlegelberger, Hildegard Büning, Bernd Auber, Axel Schambach
Published in: Medizinische Genetik, Issue Volume 32: Issue 2, 2020, ISSN 1863-5490
Publisher: De Gruyter
DOI: 10.1515/medgen-2020-2021

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells

Author(s): Michael Morgan, Hildegard Büning, Martin Sauer, Axel Schambach
Published in: Frontiers in Immunology, Issue 11, 2020, Page(s) 1965, ISSN 1664-3224
Publisher: Frontiers Media
DOI: 10.3389/fimmu.2020.01965

Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment

Author(s): Denise Klatt, Teng-Cheong Ha, Maximilian Schinke, Anton Selich, Anna Lieske, Julia Dahlke, Michael Morgan, Tobias Maetzig, Axel Schambach
Published in: Cells, Issue 9/10, 2020, Page(s) 2194, ISSN 2073-4409
Publisher: MDPI
DOI: 10.3390/cells9102194

Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages

Author(s): Dirk Hoffmann, Johanna Sens, Sebastian Brennig, Daniel Brand, Friederike Philipp, Philippe Vollmer Barbosa, Johannes Kuehle, Doris Steinemann, Daniela Lenz, Theresa Buchegger, Michael Morgan, Christine S Falk, Christoph Klein, Nico Lachmann, Axel Schambach
Published in: Journal of Personalized Medicine, Issue 11(3), 2021, Page(s) 221, ISSN 2075-4426
Publisher: MDPI
DOI: 10.3390/jpm11030221

Retroviral gene therapy in Germany with a view on previous experience and future perspectives

Author(s): Michael A Morgan, Melanie Galla, Manuel Grez, Boris Fehse, Axel Schambach
Published in: Gene Therapy, Issue 28(9), 2021, Page(s) 494-512, ISSN 1476-5462
Publisher: Nature Publishing Group
DOI: 10.1038/s41434-021-00237-x

The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cells

Author(s): Lucas Lange, Michael Morgan, Axel Schambach
Published in: Cellular and Molecular Life Sciences, Issue 78, 2021, Page(s) 4143-4160, ISSN 1420-682X
Publisher: Birkhauser Verlag
DOI: 10.1007/s00018-021-03777-y

Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor Potential

Author(s): Lucas Lange, Dirk Hoffmann, Adrian Schwarzer, Teng-Cheong Ha, Friederike Philipp, Daniela Lenz, Michael Morgan, Axel Schambach
Published in: Stem Cell Reports, Issue 14/1, 2020, Page(s) 122-137, ISSN 2213-6711
Publisher: Cell Press
DOI: 10.1016/j.stemcr.2019.11.005

Challenges and advances in translating gene therapy for hearing disorders

Author(s): Hildegard Büning, Axel Schambach, Michael Morgan, Axel Rossi, Helena Wichova, Hinrich Staecker, Athanasia Warnecke, Thomas Lenarz
Published in: Expert Review of Precision Medicine and Drug Development, Issue 5/1, 2020, Page(s) 23-34, ISSN 2380-8993
Publisher: Taylor and Francis Online
DOI: 10.1080/23808993.2020.1707077

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123

Author(s): Michael A. Morgan, Arnold Kloos, Daniela Lenz, Nadine Kattre, Juliette Nowak, Marco Bentele, Maximilian Keisker, Julia Dahlke, Katharina Zimmermann, Martin Sauer, Michael Heuser, Axel Schambach
Published in: Viruses, Issue 13, 2024, Page(s) 1365, ISSN 1999-4915
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v13071365

Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B

Author(s): Juliane W Schott, Peixin Huang, Michael Morgan, Jennifer Nelson-Brantley, Ally Koehler, Bryan Renslo, Hildegard Büning, Athanasia Warnecke, Axel Schambach, Hinrich Staecker
Published in: Molecular Therapy, 2023, ISSN 1525-0024
Publisher: Cell Press
DOI: 10.1016/j.ymthe.2023.10.018